iiinova — where your digital self keeps evolving

INCATE @incate.bsky.social · 10/09/2026

At INCATE, we provide advice, community, and funding to accelerate innovation against Antimicrobial Resistance (AMR). 💬 While we no longer post on BlueSky, you can visit our website at incate.net, follow our socials and newsletter at linktr.ee/incateurope, or email us at info@incate.net.

incate.net

How we help - INCATE

Our SupportWe support by providing advice, community and funding to accelerate the development of your innovation. We focus on the development of new treatments, and interventions that help reduce the...

000

INCATE @incate.bsky.social · 04/06/2026

In the last EC webinar, Soumya Palliyil Palil, Alessandro Mazzetti, and Thomas Meier shared lessons on moving on from academia. A must-watch for scientists, innovators, founders, and anyone curious about turning research into real-world impact. Watch here ➡️ www.youtube.com/watch?v=R9sx...

youtube.com

Entrepreneurs #6: What does it take to be an entrepreneur?

YouTube video by INCATE

000

INCATE @incate.bsky.social · 27/05/2026

Entrepreneurship is rarely as polished as it looks. Behind every startup are uncertainty, tough decisions — and breakthroughs that make it worth it. Tomorrow at EC#6, we’re talking honestly about what it really takes to build something from scratch. Join us ➡️ www.eventbrite.ch/e/entreprene...

eventbrite.ch

Entrepreneurs Club #6: "What does it take to be an entrepreneur?"

The 6th INCATE Entrepreneurs Club brings together three compelling perspectives to uncover what defines entrepreneurship.

010

INCATE @incate.bsky.social · 21/05/2026

🚀 One week to go! Real talk on entrepreneurship, with a founder, startup enabler, and venture consultant sharing what it really takes. What Does it Take to be an Entrepreneur Soumya Palliyil • Alessandro Mazzetti • Thomas Meier Save your spot ➡️ buff.ly/uWkJi1J

021

INCATE @incate.bsky.social · 20/05/2026

The wait is over 🚀 We’re happy to announce the ventures awarded Stage I by the INCATE Selection Committee! Congratulations to: 🔹 AFFIRMA BIOTECH SL 🔹 AstralytiX 🔹 i-Seq Biotechnology 🔹 Technische Universität Berlin 🔹 University of Auckland 🔹 Università di Pavia Read more ➡️

buff.ly

From discussion to discovery: meet INCATE’s new Stage I ventures - INCATE

For the first time, INCATE’s Selection Committee didn’t simply meet — they came together in person at the headquarters of one of our industry partners, creating an atmosphere in Munich filled with…

000

INCATE @incate.bsky.social · 11/05/2026

A new antibiotic hidden in a silent gene cluster — active against MRSA and VRSA. What else are bacteria hiding in genomes we’ve barely explored? Researchers uncovered **biffamycin A** using genome mining + synthetic biology. Read ➡️

buff.ly

Discovery and Biosynthesis of the Novel Glycotetrapeptide Antibiotic Biffamycin A

Genetic de-regulation of a silent biosynthetic pathway allowed isolation and characterisation of a novel glycopeptide antibiotic named biffamycin A, which harbours unprecedented 5-chloro-4-methoxy…

000

INCATE @incate.bsky.social · 06/05/2026

Big momentum from Obulytix 🚀 From joining END2AMR to shaping Europe’s AMR innovation landscape, the team is making strong moves against antimicrobial resistance. With leadership at BEAM Alliance and a feature in Euractiv, this is just the beginning. Read more ➡️ www.incate.net/building-mom...

incate.net

Building momentum: recent milestones at Obulytix - INCATE

Obulytix has had an exciting start to the year, marked [...]

000

INCATE @incate.bsky.social · 04/05/2026

What does it really take to be an entrepreneur? We’re bringing together a spinout founder, a startup enabler, and a seasoned entrepreneur to share real, no-fluff insights on the journey—challenges, mindset, and lessons learned. Join us ➡️ buff.ly/KeD3HI8 #Entrepreneurship #StartupLife #Innovation

010

INCATE @incate.bsky.social · 30/04/2026

What if part of the fight against AMR was hiding in our kitchens? New research suggests cinnamic acid (found in cinnamon) may help slow the spread of antibiotic resistance by disrupting bacterial gene transfer. Unexpected ideas like this deserve attention. Worth a read ➡️ buff.ly/JSQfvZY

000

INCATE @incate.bsky.social · 29/04/2026

💥 Our April newsletter is out! 💥 - New INCATE milestones - The Entrepreneurs Club is back! - Milestones from portfolio venture - ... and more! Read newsletter ➡ sh1.sendinblue.com/3g79gt1f9txp... Haven't you subscribed yet? Don't fall behind, subscribe here ➡ www.incate.net/newsletter/

000

INCATE @incate.bsky.social · 24/04/2026

Attention :DZIF, other DZGs, CARB-X members and INCATE portfolio planning early-phase clinical trials in translational research: DZIF PDU is hosting a free online workshop on 7 May, tailored for academic researchers working. 🗓 Registration: May 5 2026 Info & registration ➡️

buff.ly

PDU online workshop on early-phase clinical trials | German Center for Infection Research

PDU online workshop on early-phase clinical trials

000

INCATE @incate.bsky.social · 23/04/2026

Yesterday felt like a leap for INCATE. For the first time, our Selection Committee gathered in Munich at one of our industry partners facilities. Thank you to MSD Germany and all SC members for making it happen. Now… which ventures are next? Stay tuned

000

INCATE @incate.bsky.social · 22/04/2026

📢 One month left to apply for the ICARe 2026! 🗓️ Application deadline: June 21, 2026 📆 Course dates: October 10–18, 2026 📍 Les Pensières Center for Global Health, Annecy Spots are limited: secure yours now and be part of the future of antibiotic research. Info & application ➡️ www.icarecourse.org

111

INCATE @incate.bsky.social · 20/04/2026

We’re still here at #ESCMIDGlobal2026 ready to connect! No booth? No problem. The conversations are what matter most, and we’re all in. If you’ve got ideas, insights, challenges, or something exciting to share: we’re all ears! We are still around and would love to chat. Let’s make it happen!

000

INCATE @incate.bsky.social · 17/04/2026

The weekend is almost here, time for a good book. It’s been a while since we shared our community-built Phage reading list, so here’s what we’ve gathered so far. Have a title we should add? We’d love to hear it. Wishing you a relaxing, inspiring weekend

000

INCATE @incate.bsky.social · 16/04/2026

Big milestone in the fight against AMR 👏 Congrats BioVersys on the first patient, first visit in the Phase 3 BV100 trial — a key step toward new treatments for drug-resistant infections. At INCATE, we know how vital this progress is. ➡️ Read more: ir.bioversys.com/news/biovers...

020

INCATE @incate.bsky.social · 15/04/2026

We heard you 👀 With the long weekend coming up, many couldn’t join Entrepreneurs Club #6 — so we’ve moved it! 📅 May 28 | 🕔5pm CEST Join us for “What does it take to be an entrepreneur?” ! Save your spot ➡️ www.eventbrite.ch/e/entreprene... #EntrepreneursClub #StartupLife

eventbrite.ch

Entrepreneurs Club #6: "What does it take to be an entrepreneur?"

The 6th INCATE Entrepreneurs Club brings together three compelling perspectives to uncover what defines entrepreneurship.

011

INCATE @incate.bsky.social · 14/04/2026

🚀 ESCMID Global is almost here! No booth? No problem. INCATE will be in the heart of the action in Munich. Meet our team — Peter Seiler, Ina-Kristin Behrens, Holger Zimmermann & Sina Gerbach. Got ideas or insights? Let’s talk. 📩 comms@incate.net #ESCMIDglobal2026 #innovation #networking

000

INCATE @incate.bsky.social · 13/04/2026

🚀The Entrepreneurs Club is back! Join our 6th edition as 3 expert speakers share what it really takes to be an entrepreneur—through real experiences, insights, and lessons learned. Get inspired, gain practical tips, and hear fresh perspectives. Save your spot ➡️ www.eventbrite.ch/e/entreprene...

120

INCATE @incate.bsky.social · 10/04/2026

INCATE had the pleasure of joining “Antibiotic Resistance: Ways out of the Crisis” in Basel, represented by Holger, Peter, and Valéry. From cutting-edge research at the Biozentrum to engaging discussions with the AntiResist network, the event highlighted collaborative efforts to tackle AMR. #AMR

120

INCATE @incate.bsky.social · 07/04/2026

New paper dives into emerging perspectives that go beyond the usual narratives and highlight where innovation is most urgently needed. Read paper ➡️ buff.ly/mh53wW9 Curious to hear your thoughts. What stands out most to you?

000

INCATE @incate.bsky.social · 01/04/2026

💥 Our March newsletter is out! 💥 - AMR Conference insights - New INCATE milestones - Educational opportunities - ... and more! Read all about it in INCATE's Newsletter ➡ 6s05i.r.sp1-brevo.net/mk/mr/sh/6rq... Haven't subscribed yet? Don't fall behind, subscribe here ➡ www.incate.net/newsletter/

010

INCATE @incate.bsky.social · 30/03/2026

New research in International Journal of Infectious Diseases explores a twist in cystic fibrosis infections: key pathogens may have fewer defenses against bacteriophages, opening the door to entirely new treatment strategies. Read paper ➡️ www.ijidonline.com/article/S120... #CysticFibrosis

ijidonline.com

Phage Therapy in people with Cystic Fibrosis: a systematic review

Cystic fibrosis (CF) is an inherited disorder characterized by defective epithelial chloride and bicarbonate transport, resulting in abnormally viscous secretions and chronic airway obstruction [1]. F...

000

INCATE @incate.bsky.social · 26/03/2026

Big step in antibiotic innovation: Basilea Pharmaceutica has dosed the first volunteer in its Phase 1 study of BAL2420 This novel antibiotic targets LptA. 🚀 A key milestone in the fight against antimicrobial resistance. Read more ➡️ www.basilea.com#news_1594 #AMR #Antibiotics #Innovation

basilea.com

Basilea.com : Basilea

120

INCATE @incate.bsky.social · 25/03/2026

The PathoBlock Team is on the hunt for their next Life Science Manager! Ready to be part of the fight against AMR? Or know someone who is? Spread the word and help them find the perfect fit ➡️ www.linkedin.com/posts/incate...

000

INCATE @incate.bsky.social · 24/03/2026

📢 Applications for the Interdisciplinary Course on Antibiotics and Resistance (ICARe) are now open! 🗓️ Application deadline: June 21, 2026 📆 Course: October 10-18, 2026 📍 Les Pensières Center for Global Health, Annecy Info & application ➡️ buff.ly/c9b45Lr

000

INCATE @incate.bsky.social · 20/03/2026

What if penicillin could be deadly again, even to “surviving” bacteria? Some bacteria don’t resist antibiotics… they wait them out. But what if that survival mode is actually their weak spot? Are we underestimating the power of what we already have? Read here ➡️

buff.ly

Global response to antibiotic exposure reveals a critical role for nucleotide metabolism in high-level β-lactam tolerance - npj Antimicrobials and Resistance

npj Antimicrobials and Resistance - Global response to antibiotic exposure reveals a critical role for nucleotide metabolism in high-level β-lactam tolerance

000

INCATE @incate.bsky.social · 19/03/2026

What if Phages are not an alternative to antibiotics but their best partner? Phage–antibiotic combos are showing real promise against resistant infections. But: how do we pick the right phage? Dose it? Scale something so personalized? Read the Contagion_Live article ➡️

buff.ly

Phage-Antibiotic Combinations: What We Know, What We Don’t, and Where the Field Must Go Next | Contagion Live

Emerging preclinical, compassionate-use, and randomized trial data suggest phage-antibiotic combinations may benefit select patients with multidrug-resistant infections, yet critical gaps in…

010

INCATE @incate.bsky.social · 18/03/2026

2 days left to apply! Life science founders: ELSA by Life Science Factory is still open: don’t miss out! Get hands-on support with coaching, market validation, pitching & investor access. 📅 Apr–Jun 2026 | 📝 Deadline: Mar 20 Apply: lifescience-factory.com/en/program-d...

000

INCATE @incate.bsky.social · 17/03/2026

Join the 5th Young Investigator Workshop at #ESCMID2026 in Munich! 🗓 Apr 19 | 🕤 09:30 CEST 🎟 Free for ticket holders + livestream Learn, connect, and get inspired in clinical research 👇 www.ecraid.eu/articles/sig...

001

INCATE @incate.bsky.social · 16/03/2026

Did you miss the 10th AMR Conference or need a quick refresh? From bold startup ideas to tough discussions on financing innovation and the future of antimicrobial R&D, discover the key highlights from Basel. ➡️ www.incate.net/big-ideas-bo... #AMR #AMRConference #AntimicrobialResistance

incate.net

Big ideas, bold solutions: inside the 10th AMR Conference - INCATE

The 10th AMR Conference in Basel once again brought together [...]

010

INCATE @incate.bsky.social · 13/03/2026

Acinetobacter baumannii remains a major healthcare threat with rising multidrug resistance and limited treatment options. In a new @gardp.bsky.social REVIVE article, Mohamad Yasmin and Robert A. Bonomo explore the challenges and future therapies. Read here ➡️ revive.gardp.org/managing-aci...

revive.gardp.org

Managing Acinetobacter baumannii infections: Continuing therapeutic challenges - by Mohamad Yasmin and Robert A. Bonomo

The views and opinions expressed in this article are solely those of the original author(s) and do not necessarily represent those of GARDP, their donors and partners, or other collaborators and contr...

010

INCATE @incate.bsky.social · 13/03/2026

We are really happy to have you onboard the INCATE community, @ecraid.bsky.social ! Thank you for this recognition of our work

011

INCATE @incate.bsky.social · 12/03/2026

New @who.int publication: 3 TPPs for urgently needed antibiotics. They guide R&D for: - Severe MDR Gram-negative infections - Resistant Gram-positive infections in immunosuppressed/critically ill patients - Bacterial meningitis Read here ➡️ www.who.int/publications...

who.int

Target product profiles for new antibacterial agents

severe multidrug-resistant Gram-negative infections, antibiotic-resistant Gram-positive infections in immunosuppressed and critically ill patients, and community-acquired and health care-associated ba...

000

INCATE @incate.bsky.social · 11/03/2026

The 2026 Antimicrobial Resistance Benchmark from the Access to Medicine Foundation provides a valuable overview of how the pharmaceutical sector is addressing AMR. Access report here ➡️ accesstomedicinefoundation.org/news/tools-t...

accesstomedicinefoundation.org

Tools to fight AMR exist, but industry-wide action is needed to tilt the battle against superbugs | Access to Medicine

010

INCATE @incate.bsky.social · 10/03/2026

AI is accelerating antibiotic discovery , but technology alone won’t solve antimicrobial resistance. - If science is advancing, why are so few new antibiotics reaching the market? - Who will help bridge the funding gap in antimicrobial innovation? Read here ➡️ www.statnews.com/2026/03/05/a...

statnews.com

AI could revolutionize antibiotics — but the market is standing in the way

Economic reality and the persistent absence of funding stand in the way of using AI for antibiotic breakthroughs.

000

INCATE @incate.bsky.social · 03/03/2026

New collaboration at the AMR Conference 2026! We’re happy to announce that @ecraid.bsky.social has joined INCATE as a supporting partner. They will support and guide our ventures, strengthening their path toward successful development of new treatment modalities to combat #AMR. Welcome!

010

INCATE @incate.bsky.social · 03/03/2026

INCATE is at the 10th AMR Conference, come find us! Today: - Session “Non-traditional assets: the translation conundrum.” at 3pm, room Sydney - Startup Pitch Event at 6pm, room Sydney We are at Booth #9 both days. Swing by, say hello, and let’s talk about how we move the field forward together.

000

INCATE @incate.bsky.social · 02/03/2026

The pre-AMR Conference has officially kicked off: this year we host a workshop on “Development of new P. aeruginosa interventions.” A big thank you to @bsse.ethz.ch, to @nccr-antiresist.bsky.social and to @dzif.bsky.social. And most importantly, thank you to all participants and speakers!

010

INCATE @incate.bsky.social · 27/02/2026

💥 Our February newsletter is out, and what a month is has been! 💥 - INCATE nominates its first CEO - New Stage I winners - New partnership - All set for the AMR Conference! - ... and more! ➡ 6s05i.r.sp1-brevo.net/mk/mr/sh/Oyc... Haven't you subscribed yet? ➡ lnkd.in/eJ7vyBCa

110

INCATE @incate.bsky.social · 26/02/2026

🌍 Another exciting milestone for 2026! We are proud to collaborate with the Cystic Fibrosis Foundation to accelerate innovation tackling AMR. Together, we’re supporting early-stage innovators and advancing new antibacterial solutions for the CF community. Read more ➡️ www.incate.net/incate-and-c...

incate.net

INCATE and Cystic Fibrosis Foundation Collaborate to Combat Antimicrobial Resistance - INCATE

February 26, 2026— INCATE (INCubator for Antibacterial Therapies in Europe), [...]

000

INCATE @incate.bsky.social · 25/02/2026

More good news today! 🎉 Congratulations the INCATE portfolio venture mycoBiologics Ltd on their official spin-out from the University of Aberdeen. A major milestone in their journey to develop novel antibody therapies for life-threatening fungal infections.

120

INCATE @incate.bsky.social · 25/02/2026

Huge congratulations to Baxiva on securing CHF 150,000 in Venture Kick Stage III funding! 🎉 Congrats to the whole team, INCATE is proud to support Baxiva and look forward to their continued progress! Read all here ➡️ www.venturekick.ch/Baxiva-recei...

venturekick.ch

Baxiva receives CHF 150,000 from Venture Kick to develop first-in-class Escherichia Coli vaccine

ETH spin-off Baxiva has obtained CHF 150,000 from Venture Kick to advance a new vaccine designed to prevent diseases caused by Escherichia coli (E. coli). The biotech startup aims to tackle one of the...

000

INCATE @incate.bsky.social · 24/02/2026

The countdown is on: 1 week until the 10th AMR Conference! Have you secured your spot yet? 📍 Basel 📅 3–4 February 2026 Be sure to book a meeting with us through the partnering system, or simply stop by and say hello. You’ll find INCATE at Booth 9. Let’s connect, exchange ideas. See you in Basel!

010

INCATE @incate.bsky.social · 23/02/2026

Have you read this reflection on a decade of progress against AMR? What lessons should we carry into the next phase of global AMR action? And what will it take to ensure sustainable innovation, access, and responsible use? Read here ➡️ www.linkedin.com/pulse/decade...

linkedin.com

A Decade of Action on AMR: Reflections and Path to 2029

Antimicrobial resistance (AMR) remains one of the biggest threats to health and modern medicine. Antibiotics underpin much of patient safety and care, from simple surgeries and dental procedures to ca...

010

INCATE @incate.bsky.social · 19/02/2026

A 5,000-year-old bacterium (frozen in ice) can resist modern antibiotics. This changes the narrative. We’re not just causing resistance: we are accelerating an ancient arms race. Are we reacting to resistance… instead of getting ahead of it? Read more at The Independent ➡️

buff.ly

Ancient bacteria found frozen in cave resistant to 10 types of antibiotics

5,000-year-old microorganism could add to the challenge of antibiotic resistance

010

INCATE @incate.bsky.social · 17/02/2026

The updated PASTEUR Act has been reintroduced in US Congress, proposing subscription-style payments ($75M–$300M/year) to reward high-value antibiotics based on innovation and public health impact. Could this finally fix the broken antibiotic market Read more: buff.ly/6RlAnbO

010

INCATE @incate.bsky.social · 16/02/2026

The AMR Conference is almost here! ✔️ Expert speakers ✔️ Startup Pitch finalists ✔️ Poster finalists The stage is set for two days of bold ideas, innovation, and collaboration in antimicrobial resistance. Have you secured your spot yet? 📍 Basel | 3–4 February 2026 Come find INCATE at Booth 9

011

INCATE @incate.bsky.social · 14/02/2026

Is Europe’s biotech funding engine running out of fuel? With biotech financing gaps widening, investors are stepping up. But what does that really mean for innovation, startups, and the future of health tech across the continent? A must-read article with fresh insights and data ➡️

buff.ly

Europe’s life sciences investors step up as biotech financing gap widens - European Biotechnology Magazine

Europe produces world-class life sciences research, yet still struggles to finance and scale it. Venture capital in European biotech accounts for just 7 per cent of global funding, while 66 of the 67…

010